



## Cancer Metastasis and Therapeutic Resistance 2.0

Guest Editor:

**Dr. Elizabeth Shinmay Yeh**

Department of Pharmacology  
and Toxicology, Indiana  
University School of Medicine,  
Simon Comprehensive Cancer  
Center, Indianapolis, IN, USA

Deadline for manuscript  
submissions:

**closed (31 July 2023)**

### Message from the Guest Editor

Dear Colleagues,

Metastasis and resistance to cancer treatments often go hand in hand, relying on overlapping mechanisms that allow cancer to progress from its primary form to more severe disease states. These mechanisms include the activation of signaling pathways, evasion of immune surveillance, and alteration in cell surface receptors. While numerous targets and agents have been uncovered in recent years, cancer cells continue to evade these solutions. In this Special Issue, we aim to present high-quality research in these areas to share within the research community what we have learned, what is new, and what is on the cutting edge of mechanisms that cause metastasis and resistance. We welcome the submission of original research articles and review articles on signaling mechanisms, experimental therapeutics, and clinical observations.

Dr. Elizabeth Yeh

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI